Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL5874676 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Sulfuric Acid SCHEMBL28813640 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Azepane SCHEMBL29144238 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Piperidine SCHEMBL18091131 | 0.97 | ALDH1A1 (0.56) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Piperidine SCHEMBL27494539 | 0.97 | ALDH1A1 (0.56) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Piperidine SCHEMBL29877069 | 0.97 | ALDH1A1 (0.56) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Pyrrolidine SCHEMBL28642083 | 0.97 | ALDH1A1 (0.53) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Pyrrolidine SCHEMBL3835047 | 0.97 | ALDH1A1 (0.53) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Pyrrolidine SCHEMBL27815363 | 0.93 | ALDH1A1 (0.50) | ALDH1A1LMNACYP3A4GABRA1TSHR | |
| Sulfuric Acid SCHEMBL7741636 | 0.89 | CA5A (0.50) | ALDH1A1LMNACYP3A4GABRA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084053-A1 | 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | King Faisal University (SA) | 2025-03-13 | — | — | US | claimed |
| US-12178802-B1 | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound | King Faisal University (SA) | 2024-12-31 | — | — | US | claimed |
| US-11999712-B1 | 2-(benzo[b]thiophen-3-yl)-1-butyl-4,5-diphenyl-1H-imidazole as an anti-inflammatory and anti-microbial compound | King Faisal University (SA) | 2024-06-04 | — | — | US | claimed |
| US-11993579-B1 | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1h-imidazol-2-yl)pyridin-4-ol as an anti-microbial compound | King Faisal University (SA) | 2024-05-28 | — | — | US | claimed |
| US-11970475-B1 | 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antimicrobial compound | King Faisal University (SA) | 2024-04-30 | — | — | US | claimed |
| US-11958829-B1 | 3-(4,5-diphenyl-2-(pyridin-3-YL)-1H-imidazol-1-YL)-N,N-dimethylpopan-1-amine as an antimicrobial compound | King Faisal University (SA) | 2024-04-16 | — | — | US | claimed |
| US-11952361-B1 | 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl) pyridin-3-ol as an antitumor and antimicrobial compound | King Faisal University (SA) | 2024-04-09 | — | — | US | claimed |
| US-11932619-B1 | 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound | King Faisal University (SA) | 2024-03-19 | — | — | US | claimed |
| US-11905272-B1 | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| CN-105541664-B | A kind of method for synthesizing cyanoacrylate | 潍坊同业化学有限公司 | 2018-01-30 | — | — | CN | claimed |
| US-20180016231-A9 | METHOD FOR PREPARING STRUCTURED DIRECTING AGENT | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-01-18 | — | — | US | claimed |
| WO-2016172128-A1 | METHOD FOR PREPARING STRUCTURED DIRECTING AGENT | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2016-10-27 | — | — | WO | claimed |
| US-20160304457-A1 | METHOD FOR PREPARING STRUCTURED DIRECTING AGENT | JOHNSON MATTHEY PLC (GB) | 2016-10-20 | — | — | US | claimed |
| CN-105541664-A | Method for synthesizing cyanoacrylate | WEIFANG TONGYE CHEMICAL CO LTD | 2016-05-04 | — | — | CN | claimed |
| EP-1183277-B1 | SUBSTITUTED POLYSACCHARIDE SULFATES, METHOD FOR PRODUCING THEM AND THEIR USE AS HIGH-PERFORMANCE FLOW AGENTS FOR CEMENT MIXTURES | SIKA TECHNOLOGY AG (CH) | 2003-08-20 | — | — | EP | claimed |
| US-6060597-A | GLUCOSES BOUND CYCLICALLY VIA ALPHA-1,6-LINKAGES AND HAVING AT LEAST ONE S-OXO ACID GROUP BOUND | KIKKOMAN CORPORATION (JP) | 2000-05-09 | — | — | US | claimed |
| EP-0634436-B1 | SULFATE OF N-ACETYLNEURAMINIC ACID HOMOPOLYMER, PROCESS FOR PRODUCING THE SAME, ANTI-HIV DRUG CONTAINING SAID SULFATE, METHOD OF TREATING AIDS WITH SAID SULFATE, USE OF SAID SULFATE FOR TREATING AIDS, AND USE OF SAID SULFATE FOR PRODUCING THE DRUG | MARUKIN SHOYU KK (JP) | 1998-10-28 | — | — | EP | claimed |
| US-5637690-A | VIRICIDE; AIDS THERAPY | MARUKIN SHOYU CO., LTD. (JP) | 1997-06-10 | — | — | US | claimed |
| EP-0634436-A1 | SULFATE OF N-ACETYLNEURAMINIC ACID HOMOPOLYMER, PROCESS FOR PRODUCING THE SAME, ANTI-HIV DRUG CONTAINING SAID SULFATE, METHOD OF TREATING AIDS WITH SAID SULFATE, USE OF SAID SULFATE FOR TREATING AIDS, AND USE OF SAID SULFATE FOR PRODUCING THE DRUG | MARUKIN SHOYU CO., LTD. (JP) | 1995-01-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958829-B1 | 3-(4,5-diphenyl-2-(pyridin-3-YL)-1H-imidazol-1-YL)-N,N-dimethylpopan-1-amine as an antimicrobial compound | PIR, PAM, DPM1 | ALDH1A1 2038/4885LMNA 2040/4885CYP3A4 1392/4885 |
| US-11905272-B1 | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, API5, MCL1 | ALDH1A1 1200/4885LMNA 1263/4885CYP3A4 2332/4885 |
| US-11999712-B1 | 2-(benzo[b]thiophen-3-yl)-1-butyl-4,5-diphenyl-1H-imidazole as an anti-inflammatory and anti-microbial compound | IL1B, NFKBIA, IL4 | ALDH1A1 1158/4885LMNA 4735/4885CYP3A4 534/4885 |
| US-11993579-B1 | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1h-imidazol-2-yl)pyridin-4-ol as an anti-microbial compound | PIR, TLR4, IL4 | ALDH1A1 2148/4885LMNA 3844/4885CYP3A4 1230/4885 |
| US-11932619-B1 | 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound | MCL1, NCL, DCK | ALDH1A1 1482/4885LMNA 1013/4885CYP3A4 2147/4885 |
| US-12178802-B1 | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound | API5, CASP3, CASP1 | ALDH1A1 2098/4885LMNA 3599/4885CYP3A4 1471/4885 |
| US-11970475-B1 | 4-(1-(2-Hydroxypropyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antimicrobial compound | PIR, CASP4, DPP4 | ALDH1A1 1423/4885LMNA 3808/4885CYP3A4 150/4885 |
| US-11952361-B1 | 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl) pyridin-3-ol as an antitumor and antimicrobial compound | API5, CASP1, PRF1 | ALDH1A1 2137/4885LMNA 3676/4885CYP3A4 1525/4885 |
| US-20180016231-A9 | METHOD FOR PREPARING STRUCTURED DIRECTING AGENT | SDAD1, ARSA, STS | ALDH1A1 1839/4885LMNA 1880/4885CYP3A4 3110/4885 |
| US-20250084053-A1 | 3-(2-(6-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTICANCER COMPOUND | MCL1, NCL, DCK | ALDH1A1 1482/4885LMNA 1013/4885CYP3A4 2147/4885 |
| US-20160304457-A1 | METHOD FOR PREPARING STRUCTURED DIRECTING AGENT | SDAD1, ARSA, STS | ALDH1A1 1839/4885LMNA 1880/4885CYP3A4 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.